Ionis Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $27.00K.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $489.09M.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2018-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2018-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $489.12M.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2018 was $447.96M, a 524.44% increase from fiscal 2017.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2017 was $71.74M.
- Ionis Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2013 was $173.29M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $489.12M 10-K · filed 2026-02-26 |
| 2024-09-30 | $489.09M 10-Q · filed 2025-10-29 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $447.96M 10-K · filed 2021-02-24 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | |
| 2018-06-30 | $447.96M 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $71.74M 10-K · filed 2018-02-28 | |
| 2013-12-31 | $173.29M 10-K · filed 2016-02-26 | |
| 2008-12-31 | $49.96M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |